Pharmacogenetic testing, which is used to classify how patients with major depressive disorder (MDD) metabolize medications, reduces adverse drug-gene interactions, new research shows. In a randomized ...
Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies that included 3,532 ...
Major depressive disorder is linked to Th2 immune dysregulation similar to atopic dermatitis. Could dupilumab offer a new ...
Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results